ImmunoGen (IMGN)

14.32 -0.15  -1.04%  May 30, 11:09AM Go Pro
Watch this stock
View Full Chart IMGN Price Chart

Key Stats

Market Cap 1.099B
Revenue Growth -37.59%
Profit Margin -574.1%
Earnings Yield -6.28%
Dividend Yield 0.00%
Earnings Per Share TTM -0.90
PE Ratio
Price / Sales Ratio 55.20
52 Week High 16.20
52 Week Low 9.17
Beta 1.656
View Pro Ratings Details

YCharts Pro Ratings

Go Pro.
Learn More
  • Pro Value Score Go Pro
  • Pro Fundamental Score Go Pro
  • Pro Valuation from Historical Multiples Go Pro

News

May 29 Drugs To Watch At ASCO 2012
May 24 $HRL $IMGN $HL $CORT on watch list next week. by StockGravity
May 24 $IMGN http://stks.co/3yyo Trading Ideas for Fri May 25: $IMGN $BBBY $FL http://stks.co/3yyp by TraderHR
May 21 $IMGN http://stks.co/3vUP could break out of multi-month consolidation, watch for a move above $15 http://stks.co/3vUQ by TraderHR
May 17 IMMUNOGEN INC Financials
May 16 RT @adamfeuerstein Orbimed Advisors top 5 new buys in Q1: $ONXX $CCXI $IMGN $NBIX $ARRY, per 13F #biotech by WolfsBiotechs
May 16 ImmunoGen, Inc. Announces Presentations at 2012 ASCO Annual Meeting on Product Candid...
May 15 Redefining The Meaning Of 'Creating Shareholder Value' In Biotech
May 10 IV30(TM) GAINER $WIN +46.48% $PCAR +24.65% $MDR +15.21% $QLIK +13.91% $CRM +12.93% $IMGN +12.6% $AVP +10.06% $NTAP +9.69% $QIHU +9.39% by livevol_pro
May 10 $IMGN filed latest Quarterly Report http://stks.co/3lvP by MarketBrief
May 10 IMMUNOGEN INC Files SEC form 10-Q, Quarterly Report

Profile

Exchange: NASDAQGM       Sector: Healthcare       Industry: Biotechnology

ImmunoGen, Inc. develops targeted anticancer therapeutics using our expertise in cancer biology, engineered antibodies and highly potent cancer-cell killing agents. The company's Targeted Antibody Payload technology uses monoclonal antibodies to deliver one of its proprietary cancer cell killing agents specifically to tumor cells. Its products include lorvotuzumab mertansine-IMGN901, trastuzumab emtansine-T-DM1, IMGN388, IMGN529, IMGN853 and SAR3419. ImmunoGen, Inc. was founded in 1981 and is headquartered in Waltham, Massachusetts. Its manufacturing facility is in Norwood, Massachusetts.

1 Year Total Return Performance

This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). ImmunoGen is up 17.86% over the last year vs S&P 500 Total Return up 2.32%, Seattle Genetics up 2.72%, and Sangamo BioSciences down 32.43%.

  • IMGN Total Returns
  • ^SPXTR Total Returns
  • SGEN Total Returns
  • SGMO Total Returns

Fundamentals

Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.

Income Statement View Statement

Balance Sheet View Statement

Get Quote for

Pro Strategies Featuring IMGN

Did ImmunoGen make it into our Pro Portfolio Strategies?

Start your YCharts Pro membership now to find out.

IMGN Charts

Recent Quotes

Symbol Price Chg Chg % Market Cap
IMGN 14.32 -0.15 -1.04% 1.111B
IMC 15.21 -0.07 -0.47%
IMAX 21.42 -0.55 -2.50% 1.435B
IM 18.02 -0.07 -0.39% 2.715B
ILMN 44.20 +0.00 +0.00% 5.448B
ILF 40.15 -0.64 -1.57%
IL 4.07 -0.14 -3.33% 230.50M
MCD 90.01 -0.89 -0.98% 92.59B
MCBF 1.15 -0.09 -7.26% 2.358M
MCBC 3.278 +0.03 +0.85% 88.76M
You must be signed in to use watchlists.
Sign In or Register
Create Watchlist from Stock Quotes
Close